TABLE 2.
Main assumptions for the cost-effectiveness analysis.
| Parameter | Baseline value | Upper and lower limits | Distribution | Source |
|---|---|---|---|---|
| Event incidence rate, annual | ||||
| Incidence of MI (statin group) | 2.34% | 1.87%–2.81% | β distribution | In-hospital data |
| RR of MI (inclisiran VS statin) | 0.68 | 0.48–0.96 | β distribution | Luo et al. (2023) |
| Incidence of revascularization | 3.2% | 2.56%–3.84% | β distribution | Ray et al.(2020); Cholesterol Treatment Trialists’ CTT Collaboration et al. (2010) |
| MI recurrence | 4.1% | 3.9%–4.9% | β distribution | Song et al. (2020) |
| Rate of rehabilitation treatment in the post-MI state | 9.96% | 7.97%–11.95% | β distribution | In-hospital data |
| Non-CVD death | Life Table | 3.36‰–5.04‰ | β distribution | National Demographic Data of National Bureau of Statistics (2020) |
| MI death | 25× non-CVD death | 8.4%–12.6% | β distribution | National Demographic Data of National Bureau of Statistics (2020); Song et al. (2020) |
| Death during the post-MI state | 2.1% | 1.68%–2.52% | β distribution | Song et al. (2020) |
| Cost | ||||
| Inclisiran (RMB/USD)/injection | RMB 20,000.00 USD 2,973.49 |
RMB 16,000–24,000 USD 2,378.79–3,568.19 |
γ distribution | In-hospital data |
| Statin (RMB/USD)/tablet, daily, 20 mg/tablet | RMB 3.45 USD 0.51 |
RMB 2.76–4.14 USD 0.41–0.62 |
γ distribution | In-hospital data |
| MI therapeutic treatment fee (RMB/USD)/year | RMB 30,381.30 USD 4,516.93 |
RMB 24,305.04–36,457.56 USD 3,613.54–5,420.31 |
γ distribution | Statistical Information CenterNational Health and Health Commission of the People’s Republic of China (2020) |
| Revascularization cost (RMB/USD)/year | RMB 68,625.6 USD 10,202.88 |
RMB 59,400.48–82,350.72 USD 88,3,134–12,243.46 |
γ distribution | Statistical Information CenterNational Health and Health Commission of the People’s Republic of China (2020) |
| Laboratory test fee (RMB(USD)/time | RMB 211.00 USD 31.37 |
RMB 168.8–253.2 USD 25.10–37.64 |
γ distribution | In-hospital data |
| Rehabilitation cost (first year) (RMB/USD)/year | RMB 18,758.5 USD 2,788.91 |
RMB 15,006–22,510 USD 2231.01–3346.66 |
γ distribution | In-hospital data |
| Rehabilitation cost (after first year) (RMB/USD)/year | RMB 10,800 USD 1,605.69 |
RMB 8,540–12,960 USD 1,269.68–1,926.82 |
γ distribution | In-hospital data |
| Utility value | ||||
| Pre-MI | 0.84 | 0.73–0.95 | β distribution | Wang (2021) |
| Post-MI | 0.80 | 0.69–0.91 | β distribution | Wang (2021) |
| Recurrent MI (decrement) | 0.06 | β distribution | Lewis et al. (2014) | |
| Coronary revascularization (decrement) | 0.07 | β distribution | van Stel et al. (2012) | |
| Discounting | 5% | 0–8% | ||